Results 41 to 50 of about 26,327 (353)

Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena

Journal of Diabetes, 2023
AbstractNeprilysin (NEP) is a transmembrane zinc‐dependent metalloproteinase that inactivates various peptide hormones including glucagon‐like peptide 1 (GLP‐1). NEP inhibitors may be effective in the management of type 2 diabetes mellitus (T2DM) by increasing the circulating level of GLP‐1.
Faisal Holil AlAnazi, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Athanasios Alexiou, Marios Papadakis, Hanan A. Ogaly, Yousef Abud Alanazi, Hebatallah M. Saad, Gaber El‐Saber Batiha   +8 more
openaire   +2 more sources

Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases

Biology, 2022
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) activate the guanylyl cyclase A receptor (GC-A), which synthesizes the second messenger cGMP in a wide variety of tissues and cells.
Hitoshi Nakagawa, Yoshihiko Saito
doaj   +1 more source

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure [PDF]

, 2015
The clinical syndrome of heart failure is one of the leading causes of hospitalisation and mortality in older adults. An association between cognitive impairment and heart failure is well described but our understanding of the relationship between the ...
Cannon, Jane A., McMurray, John J.V., Quinn, Terry J.   +2 more
core   +4 more sources

Blockade of the Neprilysin and Angiotensin Ameliorates Oxidative Stress in the Cardiovascular Target Tissues of Dexamethasone-induced Hypertensive Rats

Haseki Tıp Bülteni, 2020
Aim:The imbalance between production of reactive oxygen species and antioxidant defense determines the degree of oxidative toxicity and severity of subsequent myocardial damage.We aimed to evaluate the anti-oxidative effects of neprilysin and angiotensin
Duygun Altıntaş Aykan, Muhammed Seyithanoğlu, Nadire Eser, Burak Tanrıverdi, Yaman Selma   +4 more
doaj   +1 more source

Changes in Aβ42, Neprilysin, and γ-Secretase in the Hippocampus of Male Rats Alzheimer’s model: The Effects of Aerobic Training and Omega-3 Intake [PDF]

Journal of Kerman University of Medical Sciences, 2023
Background: Alzheimer›s disease (AD) is characterized by excessive deposition of the amyloid-β peptide (Aβ) in the central nervous system and reducing its level is the goal of many medications.
Ali Yaghoubi
doaj   +1 more source

Angiotensin receptor blocker neprilysin inhibitors

World Journal of Cardiology, 2021
Heart failure (HF) is a clinical syndrome that results from a structural or functional cardiac disorder that reduces the ability of the ventricle of the heart to fill with, or eject, blood. It is a multifaceted clinical condition that affects up to 2% of the population in the developed world, and is linked to significant morbidity and mortality; it is ...
Suguru Asako, Ippei Osugi, Tomohisa Nomura, Daisuke Usuda, Manabu Sugita, Kenki Usami, Toshihiro Higashikawa, Shintaro Shimozawa, Keiko Mizuno, Takayuki Komatsu, Risa Katou, Toshihiko Yoshizawa, Sakurako Ito, Shungo Tokunaga, Akihiko Kondo, Hiroki Takami, Yuta Hotchi, Jiro Oba, Kentaro Mishima   +18 more
openaire   +3 more sources

Expression of Neprilysin in Skeletal Muscle by Ultrasound-Mediated Gene Transfer (Sonoporation) Reduces Amyloid Burden for AD

Molecular Therapy: Methods & Clinical Development, 2020
Amyloid β (Aβ) accumulation in the brain is considered to be one of the major pathological changes in the progression of Alzheimer’s disease (AD). Neprilysin (NEP) is a zinc metallopeptidase that efficiently degrades Aβ.
Yuanli Li, Yadi Wang, Jue Wang, Ka Yee Chong, Jingjing Xu, Zhaohui Liu, Chunlei Shan   +6 more
doaj   +1 more source

Role of Renal Sympathetic Nerves in GLP‐1 (Glucagon‐Like Peptide‐1) Receptor Agonist Exendin‐4‐Mediated Diuresis and Natriuresis in Diet‐Induced Obese Rats

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background The gut‐derived hormone GLP‐1 (glucagon‐like peptide‐1) exerts beneficial effects against established risk factors for chronic kidney disease.
Xuefei Liu, Kaushik P. Patel, Hong Zheng
doaj   +1 more source

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition

Asian Journal of Medical Sciences, 2017
Background: Current Heart failure (HF) pharmacotherapy has been unsatisfactory in halting disease progression completely. Aims and Objective: To evaluate the role of LCZ696, a recent FDA-approved ACE -Neprilysin inhibitor (ARNi) in the management of ...
Sandeep Lahiry
doaj   +1 more source